{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:50Z","timestamp":1789726370399,"version":"4.0.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Daptomycin has been associated with increased creatine phosphokinase (CPK) due to muscle injury leading to myalgias and muscle weakness. Statins have been proven to cause the same effects and it is recommended to discontinue the use of statins while on daptomycin. Evidence regarding this drug interaction is mixed. This study evaluated the risk of CPK elevation in concomitant use of daptomycin and statins compared to daptomycin alone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>This is a multisite retrospective case-control study of patients who received daptomycin therapy with monitoring of CPK. Rates of CPK elevations were compared in patients receiving daptomycin with a statin versus daptomycin alone. To estimate the association between CPK elevation and daptomycin therapy controlling for other risk factors, logistic regression was used to analyze data. Statistical significance was determined at \u0251 of 0.05.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 3658 patients were included in the study, with 2787 on daptomycin therapy alone and 871 with concurrent statin use. The incidence of CPK elevation was 90 events (3.2%) in the daptomycin group and 26 events (3.0%) in the concurrent statin group. Patients who received daptomycin therapy in addition to statins had no statistically significant difference from patients on daptomycin alone (hazard ratio, 1.05; P = .85; 95% confidence interval, 0.61\u20131.84). After adjusting for potential risk factors, the hazards ratio remained almost the same.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Concomitant use of daptomycin and statin did not show an increase risk of CPK elevation. Clinicians may consider concomitant use of daptomycin and statin therapy with weekly CPK monitoring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofz444","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T20:06:09Z","timestamp":1573157169000},"source":"Crossref","is-referenced-by-count":15,"title":["A Retrospective Multisite Case-Control Series of Concomitant Use of Daptomycin and Statins and the Effect on Creatine Phosphokinase"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-0851","authenticated-orcid":false,"given":"Bethany","family":"Lehman","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Neuner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Heh","sequence":"additional","affiliation":[{"name":"CORE Research Office, Ohio University Heritage College of Osteopathic Medicine, Dublin, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Isada","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"2019110802282773000_CIT0001","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2019110802282773000_CIT0002","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for Gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2019110802282773000_CIT0003","article-title":"Cubicin (daptomycin for injection): highlights of perscribing information","author":"Food and Drug Administration."},{"key":"2019110802282773000_CIT0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/dmdi-2012-0033","article-title":"Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability","volume":"28","author":"Golightly","year":"2013","journal-title":"Drug Metabol Drug Interact"},{"key":"2019110802282773000_CIT0005","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/01.wnl.0000269789.09277.47","article-title":"Statin treatment withdrawal in ischemic stroke: a controlled randomized study","volume":"69","author":"Blanco","year":"2007","journal-title":"Neurology"},{"key":"2019110802282773000_CIT0006","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1001\/archinte.164.19.2162","article-title":"Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction","volume":"164","author":"Spencer","year":"2004","journal-title":"Arch Intern Med"},{"key":"2019110802282773000_CIT0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/1060028013514377","article-title":"Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy","volume":"48","author":"Berg","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2019110802282773000_CIT0008","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-014-0041-y","article-title":"Effect of concomitant 3-Hydroxy-3-methyl-glutaryl-CoA reductase inhibitor therapy on creatine phosphokinase levels and mortality among patients receiving daptomycin: retrospective cohort study","volume":"3","author":"McConnell","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2019110802282773000_CIT0009","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/ciy287","article-title":"Effect of statin coadministration on the risk of daptomycin-associated myopathy","volume":"67","author":"Dare","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019110802282773000_CIT0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3949\/ccjm.83a.14120","article-title":"Approach to asymptomatic creatine kinase elevation","volume":"83","author":"Moghadam-Kia","year":"2016","journal-title":"Cleve Clin J Med"},{"key":"2019110802282773000_CIT0011","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s10096-011-1500-y","article-title":"Safety analysis of high dose (>6 mg\/kg\/day) daptomycin in patients with concomitant statin therapy","volume":"31","author":"Parra-Ruiz","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019110802282773000_CIT0012","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/AAC.02910-14","article-title":"Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors","volume":"58","author":"Bland","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019110802282773000_CIT0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":"The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2019110802282773000_CIT0014","first-page":"128","article-title":"Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants","volume":"5","author":"Talameh","year":"2014","journal-title":"J Pharmacogenomics Pharmacoproteomics"},{"key":"2019110802282773000_CIT0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1517\/14740338.2012.670633","article-title":"Simvastatin interactions with other drugs","volume":"11","author":"Florentin","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"2019110802282773000_CIT0016","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"2019110802282773000_CIT0017","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/mus.21691","article-title":"Characterization of skeletal muscle effects associated with daptomycin in rats","volume":"42","author":"Kostrominova","year":"2010","journal-title":"Muscle Nerve"},{"key":"2019110802282773000_CIT0018","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11626-010-9311-5","article-title":"Effect of daptomycin on primary rat muscle cell cultures in vitro","volume":"46","author":"Kostrominova","year":"2010","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"2019110802282773000_CIT0019","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-140-11-200406010-00006","article-title":"Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study","volume":"140","author":"Spencer","year":"2004","journal-title":"Ann Intern Med"},{"key":"2019110802282773000_CIT0020","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1161\/STROKEAHA.109.552760","article-title":"Withdrawal of statins and risk of subarachnoid hemorrhage","volume":"40","author":"Risselada","year":"2009","journal-title":"Stroke"},{"key":"2019110802282773000_CIT0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Chong","year":"2007","journal-title":"JAMA"},{"key":"2019110802282773000_CIT0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/heart.88.3.229","article-title":"Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study","volume":"88","author":"Wei","year":"2002","journal-title":"Heart"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/11\/ofz444\/30488256\/ofz444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/11\/ofz444\/30488256\/ofz444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T15:44:40Z","timestamp":1573227880000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz444\/5614412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz444","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,11,1]]},"article-number":"ofz444"}}